Pleiotropic effects of statins in systemic sclerosis

Terapevticheskii Arkhiv

Volumn 83, Issue 5, 2011, Pages 41-47

  Alekperov, R T ^a   Korzeneva, E G ^a   Alexandrova, E N ^a   Novikov, A A ^a   Ananyeva, L P ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

Angiogenic factors; Endothelial dysfunction; Inflammation; Statins; Systemic sclerosis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; AGED; C-REACTIVE PROTEIN; CYTOKINES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960969618     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 2007;117:557-567. (Pubitemid 46348510)
2. Leroy E. C. Systemic sclerosis: a vascular perspective. Rheum. Dis. Clin. N. Am. 1996;22:695-708.
3. Koch A. E., Kronfield-Harrington L. B., Szechnech A. et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993;61:239-246. (Pubitemid 24007481)
4. Claman H. N., Giorno R. C., Seibold J. R. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthr. and Rheum. 1991;34:1495-1501.
5. White B. Immunologic aspects of scleroderma. Curr. Opin. Rheumatol. 1995;7:541-545.
6. Freedman R. R., Girgis R., Mayes M. D. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J. Rheumatol. 2001;28(1):119-121. (Pubitemid 32062033)
7. Goto K., Kasuya Y., Maysuki N. et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. USA 1989;86:3915-3918. (Pubitemid 19141853)
8. Anderson M. E., Moore T. L., Hollis S. et al. Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin. Exp. Rheumatol. 2003;21:403. (Pubitemid 36747842)
9. La Civita L., Rossi M., Vagheggini G. et al. Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann. Rheum. Dis. 1998;57:52-55. (Pubitemid 28175222)
10. Schlez A., Kittel M., Braun S. et al. Endothelium-dependent regulation of cutaneous microcirculation in patients with systemic scleroderma. J. Invest. Dermatol. 2003;120:332-334. (Pubitemid 36513086)
11. Boin F., Wigley F. M. Understanding, assessing and treating Raynaud's phenomenon. Curr. Opin. Rheumatol. 2005;17:752-760. (Pubitemid 41546495)
12. Thompson A. E., Shea B., Welch V. et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthr. and Rheum. 2001;44(8):1841-1847. (Pubitemid 32758232)
13. Fisher M., Grotta J. New uses for calcium channel blockers: therapeutic implications. Drugs 1993;46:961-975. (Pubitemid 24016640)
14. Nannini C., West C. P., Erwin P. J., Matteson E. L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthr. Res. Ther. 2008;10:R124.
15. Mayes M. D., Lacey J. V., Beebe-Dimmer J. et al. Prevalence, incidence, sutvival, and disease characteristics of systemic sclerosis in a large US population. Arthr. and Rheum. 2003;48(8):2246-2255. (Pubitemid 36959206)
16. Steen V. D., Medsger T. A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 2007;66:940-944. (Pubitemid 46999798)
17. The long-term intervention with pravastatin in ischemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349-1357.
18. Sacks F. M., Pfeffer M. A., Moye L. A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996;335:1001-1009. (Pubitemid 26338729)
19. Node K., Fujita M., Kitakaze M. et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopatic dilated cardiomyopathy. Circulation 2003;108:839-843. (Pubitemid 37022126)
20. Kobashigava J. A., Katznekson S., Laks H. et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 1995;333(10):621-627.
21. Wenke K., Meiser B., Thiery J. et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a fouryear randomized trial. Circulation 1997;96:1398-1402. (Pubitemid 27375328)
22. Kwak B. R., Mulhaupt F., Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmune Rev. 2003;2:332-338. (Pubitemid 37211387)
23. Vaughan C. J., Gotto A. M., Basson C. T. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 2000;35:1-10. (Pubitemid 30061252)
24. Ridker P. M., Rifai N., Pfeffer M. A. et al. Longterm effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235. (Pubitemid 29340127)
25. Bernot D., Benoliel A. M., Peiretti F., Lopez S. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J. Cardiovasc. Pharmacol. 2003;41:316-324. (Pubitemid 36135258)
26. Zapolska-Downar D., Siennicka A., Kaczmarczyk M. et al. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci. 2004;75:1287-1302. (Pubitemid 38845028)
27. Romano M., Diomede L., Sironi M. et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 2000;80:1095-1100. (Pubitemid 30483228)
28. Wang H. R., Li J. J., Huang C. X. et al. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin. Chim. Acta 2005;353:53-60.
29. Nawawi H, Osman N. S., Yusoff K., Khalid B. A. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm. Metab. Res. 2003;35:479-485. (Pubitemid 37204564)
30. Ascer E., Bertolami M. C., Venturinelli M. L. et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-166. (Pubitemid 39361151)
31. Xu Z. M., Zhao S. P., Li Q. Z. et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin. Chim. Acta 2003;338:17-24.
32. Rezaie-Majd A., Maca T., Bucek R. A. et al. Simvastatin reduces expression or cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002;22:1194-1199. (Pubitemid 34764873)
33. Abeles A. M., Pillinger M. H. Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy? Arthr. and Rheum. 2006;54(2):393-407. (Pubitemid 43228614)
34. Jury E. C., Ehrenstein M. R. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005;14:192-196. (Pubitemid 40445582)
35. Derk C. T., Jimenez S. A. Statins and the vasculopathy of systemic sclerosis: Potential therapeutics agents? Autoimmunity Rew. 2005;1:25-32.
36. McCarey D. W., McInnes I. B., Madhok R. et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004;363:2015-2021. (Pubitemid 38781100)
37. Kanda H., Yokota K., Kubo K. et al. Simvastatin reduces the disease activity in patients with rheumatoid arthritis [abstract]. Arthr. and Rheum. 2004;50(Suppl. 9):S387.
38. Kotyla P. J., Sliwinska-Kotyla B., Kucharz E. J. TNF alpha as potential target in the treatment of SLE: a role of HMG-CoA reductase inhibitor simvastatin. J. Rheumatol. 2006;33:2361.
39. Ferreira G. A., Navarro T. P., Telles R. W. et al. Atorvastatin therapy improves endothelial-dependent vasodilatation in systemic lupus erythematosus patients: an 8 weeks controlled trial. Rheumatology 2007;46:1560-1565. (Pubitemid 47500570)
40. Masi A. T., Rodnan G. P., Medsger T. A. et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr. and Rheum. 1980;23(5):581-590. (Pubitemid 10101764)
41. Smith G. P., Chan E. S. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr. Rheumatol. Rep. 2010;12(1):26-33.
42. Smith E. A., Kahaleh M. B., LeRoy E. C. The acute phase response in scleroderma. Differing responses to intravenous PGE1. Clin. Exp. Rheumatol. 1986;4(4):341-345. (Pubitemid 17223170)
43. Blann A. D., Illingworth K., Jayson M. I. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J. Rheumatol. 1993;20(8):1325-1330. (Pubitemid 23310983)
44. Stuart R. A., Littlewood A. J., Maddison P. J., Hall N. D. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin. Exp. Rheumatol. 1995;13(1):17-22.
45. Scala E., Pallota S., Frezzolini A. et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin. Exp. Immunol. 2004;138:540-546. (Pubitemid 39573637)
46. Allanore Y., Borderie D., Lemarechal H. et al. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J. Rheumatol. 2003;30(1):68-73. (Pubitemid 36077774)
47. Akesson A., Scheja A., Lundin A., Wollheim F. A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthr. and Rheum. 1994;37(5):729-735. (Pubitemid 24145078)
48. Bolster M. B., Ludwicka A., Sutherland S. E. et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthr. and Rheum. 1997;40:743-751.
49. Hasegawa M., Sato S., Fujimoto M. et al. Serum levels of interleukin-6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp 130 in patients with systemic sclerosis. J. Rheumatol. 1998;25(2):308-313. (Pubitemid 28088260)
50. Matucci-Cerinic M., Pignone A., Biagini M., Lotti T. Markers of disease activity in systemic sclerosis. Clin. Dermatol. 1994;12:291-297. (Pubitemid 24198736)
51. Denton C. P., Bickerstaff M. C., Shiwen X. et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br. J. Rheumatol. 1995;34(11):1048-1054. (Pubitemid 26013507)
52. Distler O., Distler J. H., Scheid A. et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res. 2004;95:109-116. (Pubitemid 38931842)
53. Davies C. A., Jeziorska M., Freemont A. J., Herrick A. L. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum. Pathol. 2006;37:190-197. (Pubitemid 43099839)
54. Choi J. J., Min D. J., Cho M. L. et al. Elevated vascular endothelial growth factor in systemic sclerosis. J. Rheumatol. 2003;30:1529-1533.
55. Abou-Raya A., Abou-Raya S., Helmi M. 3-hydroxy-3-methyl glutaryl-coenzyme A (HMG-COA) reductase inhibitors (statins): a potentially valid addition to the therapeutic armamentarium of systemic sclerosis. Ann. Rheum. Dis. 2006;65(Suppl. II):38.
56. Kuwana M., Kaburaki J., Okazaki Y. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthr. and Rheum. 2006;54(6):1946-1951. (Pubitemid 43877944)
57. Furukawa S., Yasuda S., Amengual O. et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann. Rheum. Dis. 2006;65:1118-1120. (Pubitemid 44133283)
58. Del Papa N., Cortiana M., Comina D. P. et al. Clinical and biological evidences of improvement of vascular endothelial function by simvastatin in patients with systemic sclerosis. Ann. Rheum. Dis. 2007;66(Suppl. II):207.